ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.682,11
0,00%
S&P 500
5.307,01
-0,27%
Dow Jones
39.671,04
-0,51%
Euro vs US Dollar
1,08264
0,01%
Bitcoin
69.563,91
0,67%
Registration Strip Icon for alerts Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Gracell Biotechnologies Inc (GRCL)

  7. Gracell Biotechnologies Inc (GRCL) News

GRCL

Gracell Biotechnologies (GRCL)

Gracell Biotechnologies Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:GRCL
DatumZeitQuelleÜberschriftSymbolFirma
04/03/202418h22Edgar (US Regulatory)Form 15-12G - Securities registration termination [Section 12(g)]NASDAQ:GRCLGracell Biotechnologies Inc
28/02/202406h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:GRCLGracell Biotechnologies Inc
26/02/202423h28Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:GRCLGracell Biotechnologies Inc
26/02/202423h28Edgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:GRCLGracell Biotechnologies Inc
26/02/202423h26Edgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:GRCLGracell Biotechnologies Inc
26/02/202423h26Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:GRCLGracell Biotechnologies Inc
22/02/202414h50Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GRCLGracell Biotechnologies Inc
22/02/202414h45GlobeNewswire Inc.Gracell Biotechnologies Acquisition CompletedNASDAQ:GRCLGracell Biotechnologies Inc
20/02/202414h22Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GRCLGracell Biotechnologies Inc
20/02/202413h45GlobeNewswire Inc.Gracell Biotechnologies Announces Shareholders’ Approval of Merger AgreementNASDAQ:GRCLGracell Biotechnologies Inc
14/02/202414h20Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:GRCLGracell Biotechnologies Inc
30/01/202412h02Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GRCLGracell Biotechnologies Inc
29/01/202413h00GlobeNewswire Inc.Gracell Biotechnologies Announces FDA Clearance of IND Application for Phase 1 Clinical Trial of FasTCAR-T GC012F as Early-Line Treatment of Multiple MyelomaNASDAQ:GRCLGracell Biotechnologies Inc
17/01/202422h30Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GRCLGracell Biotechnologies Inc
08/01/202422h01Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GRCLGracell Biotechnologies Inc
08/01/202416h06PR Newswire (US)Kuehn Law Encourages KRTX, DSKE, RYZB, and GRCL Investors to Contact Law FirmNASDAQ:GRCLGracell Biotechnologies Inc
26/12/202314h12Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GRCLGracell Biotechnologies Inc
26/12/202312h44Dow Jones NewsGracell ADSs Take Flight Premarket on $1.2 Billion Takeover by AstraZenecaNASDAQ:GRCLGracell Biotechnologies Inc
26/12/202309h05Dow Jones NewsAstraZeneca to Buy Gracell Biotechnologies for $1.2 BillionNASDAQ:GRCLGracell Biotechnologies Inc
26/12/202308h01Business WireAstraZeneca to acquire Gracell, furthering cell therapy ambition across oncology and autoimmune diseasesNASDAQ:GRCLGracell Biotechnologies Inc
26/12/202308h00GlobeNewswire Inc.Gracell Biotechnologies to be acquired by AstraZeneca, furthering cell therapy ambition across oncology and autoimmune diseasesNASDAQ:GRCLGracell Biotechnologies Inc
22/12/202312h03Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GRCLGracell Biotechnologies Inc
21/12/202313h00GlobeNewswire Inc.Gracell Biotechnologies Announces China NMPA Clearance for IND Application for Phase 1/2 Clinical Trial of FasTCAR-T GC012F for the Treatment of Refractory Systemic Lupus ErythematosusNASDAQ:GRCLGracell Biotechnologies Inc
18/12/202322h00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GRCLGracell Biotechnologies Inc
12/12/202301h30GlobeNewswire Inc.Gracell Biotechnologies Presents Updated Clinical Data from FasTCAR-T GC012F Demonstrating Deep and Durable Responses in Newly Diagnosed Multiple Myeloma at ASH 2023NASDAQ:GRCLGracell Biotechnologies Inc
29/11/202312h18IH Market NewsAmazon Unveils Innovative Services, Okta Discloses Data Breach, Textron Plans 2% Global Workforce Reduction, and MoreNASDAQ:GRCLGracell Biotechnologies Inc
28/11/202320h59Dow Jones NewsCabaletta Bio Down as FDA Looks Into Issues With Several Companies' Approved CAR T DrugsNASDAQ:GRCLGracell Biotechnologies Inc
27/11/202314h00GlobeNewswire Inc.Gracell Biotechnologies Announces FDA Clearance of IND Application for Phase 1/2 Clinical Trial of FasTCAR-T GC012F for the Treatment of Refractory Systemic Lupus ErythematosusNASDAQ:GRCLGracell Biotechnologies Inc
21/11/202312h25Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:GRCLGracell Biotechnologies Inc
16/11/202314h00GlobeNewswire Inc.Gracell Biotechnologies to Participate in Inaugural Cell Therapy for Autoimmune Disease SummitNASDAQ:GRCLGracell Biotechnologies Inc
 Showing the most relevant articles for your search:NASDAQ:GRCL

Kürzlich von Ihnen besucht

TG
DTE
Deutsche Telekom
NASDAQ
AMZN
Amazon.com
NASDAQ
QQQ
Invesco QQQ Trust Series 1
TG
BAYN
Bayer
USOTC
RHHBY
Roche (QX)
USOTC
BASFY
BASF (QX)
TG
MBG
MercedesBenz
NASDAQ
TSLA
Tesla
NYSE
MCD
McDonalds
TG
LHA
Deutsche Lufthansa
TG
RHM
Rheinmetall
USOTC
DTEGY
Deutsche Telekom (QX)
COIN
SOLUSD
Solana
NYSE
MRK
Merck
TG
ALV
Allianz
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten